drugset / Trial / NCT05829603

Dose-finding Study for the Combination of DMT and Harmine in Healthy Subjects

NCT05829603

Phase 1 Completed 16 enrolled Reconnect Labs
RandomizedParallel-groupSingle-blindOther

Summary

The goal of this clinical trial is to compare corresponding inter- and intraindividual pharmacokinetic and pharmacodynamic profiles including assessments of safety \& tolerability.

Timeline

Start
2023-05-05
Primary completion
2023-09-17
Completion
2023-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Dimethyltryptamin Unknown
Subject Harmine Small molecule

Indications

No indication recorded.